Geriatric Prescribing: Precision Titration and Safety for Older Adults

The integration of medical cannabis into the pharmacological regimen of geriatric patients requires a paradigm shift from traditional prescribing. In older adults, the physiological context is defined by a relative increase in body fat, a decrease in total body water, and a gradual decline in hepatic and renal clearance. These factors significantly alter the pharmacokinetics of cannabinoids, particularly the distribution and elimination of THC and CBD. Therefore, the clinical objective is not merely symptom relief, but the maintenance of the patient's functional homeostatic balance, avoiding the risks of polypharmacy and adverse drug-drug interactions.

Pharmacokinetic Considerations in the Aging Patient

Age-related physiological changes directly impact how cannabinoids are processed. Since THC is highly lipophilic, the increase in adipose tissue ratio in older adults can lead to a more extensive volume of distribution and a longer half-life, as cannabinoids are sequestered in fat stores. This increases the risk of cumulative effects if the dosing frequency is too high. Furthermore, since cannabinoids are primarily metabolized by the cytochrome P450 (CYP) enzyme system—specifically CYP3A4 and CYP2C9—the potential for interactions with common geriatric medications (such as anticoagulants, anticonvulsants, or antihypertensives) must be carefully monitored. A decrease in hepatic blood flow and first-pass metabolism means that even low oral doses can result in higher-than-expected plasma concentrations.

The 'Start Low, Go Slow' Protocol in Practice

In geriatric medicine, the titration protocol is the most critical tool for safety. Evidence from observational studies suggests that older adults achieve therapeutic benefits at significantly lower doses than younger populations. For a patient naive to cannabis, the initiation should focus on formulations with low THC content or CBD-dominant profiles, depending on the indication.

The initial dose should be administered at night to mitigate the risk of dizziness or orthostatic hypotension, which could lead to falls—a primary concern in this demographic. Titration should not occur daily. Instead, it is recommended to maintain a steady dose for at least five to seven days before considering an incremental adjustment. This "Go Slow" approach allows the clinician to observe the steady-state response and ensures the central nervous system has time to adapt to the exogenous cannabinoids.

Monitoring and Dose Optimization

The success of cannabinoid therapy in the elderly is measured by the improvement in quality of life and the reduction of 'pill burden' rather than the total elimination of symptoms. Monitoring should include objective assessments of cognitive function, balance, and sleep quality. Clinical reports indicate that when titration is managed precisely, patients may be able to reduce their reliance on benzodiazepines or opioids, which carry a much higher risk profile for respiratory depression and cognitive impairment.

During follow-up, it is essential to evaluate the ‘therapeutic window,’ which in geriatric patients is notably narrow. If the patient reports dry mouth, mild confusion, or increased fatigue, the dose should be reduced to the previous tolerated level. The goal is to reach the lowest effective dose that provides relief without compromising the patient's autonomy or mental clarity. Direct communication between the pharmacist, the physician, and the caregiver is indispensable to ensure the titration schedule is followed strictly.